Evidence map›Paper›PMID 33877384›Full record

ArticleCancer immunology, immunotherapy : CII2021

Nutrient supplements from selected botanicals mediated immune modulation of the tumor microenvironment and antitumor mechanism.

Hui-Ming Chen, Linus Sun, Ping-Ying Pan, Lu-Hai Wang, Shu-Hsia Chen

Open access · greenAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Hui-Ming ChenDepartment of Oncological Sciences, Icahn School of Medicine At Mount Sinai, New York, 10029, USA.
Linus SunDepartment of Ophthalmology, Columbia University, New York, 10027, USA.
Ping-Ying PanDepartment of Oncological Sciences, Icahn School of Medicine At Mount Sinai, New York, 10029, USA.
Lu-Hai WangInstitute of Integrated Medicine and Chinese Medical Research Center, China Medical University, Taichung, 40402, Taiwan, ROC. luhaiwang@mail.cmu.edu.tw.
Shu-Hsia ChenDepartment of Oncological Sciences, Icahn School of Medicine At Mount Sinai, New York, 10029, USA. shuhsia.chen@houstonmethodist.org.ORCID http://orcid.org/0000-0002-9168-5775
Houston Methodist · USChina Medical University · TWColumbia University · US

Funding

Intervention of immune tolerance by small molecules to enhance immune therapyR01CA127483 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, SHU-HSIA · 2008 to 2018
$3.4M
Myeloid Suppressor Cell-Mediated Immune Suppression of Tumor Specific T CellsR01CA109322 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CHEN, SHU-HSIA · 2006 to 2015
$3.2M
LILRB modulates tumor microenvironment and promotes tumor progressionR01CA204191 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, SHU-HSIA · 2017 to 2022
$2.2M
Novel therapy targeting refractory colon cancerR01CA188610 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI PAN, PING-YING · 2015 to 2019
$1.8M
HSC Derived MDSC for the Prevention of GHVD Without Suppressing GvLR01CA140243 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PAN, PING-YING · 2011 to 2015
$1.7M
NCI NIH HHS R01 CA109322NCI NIH HHS R01 CA127483NCI NIH HHS R01 CA140243NCI NIH HHS R01 CA188610NCI NIH HHS R01 CA204191NIH HHS CA20419NIH HHS R01CA109322NIH HHS R01CA127483NIH HHS R01CA140243NIH HHS R01CA188610
6 · The paper itself

Abstract

Specific extracts of selected vegetables (SV) have been shown to benefit the survival of stage IIIb/IV non-small cell lung cancer patients in phase I/II studies and is currently in a phase III trial. However, the underlying mechanism of SV-mediated antitumor immune responses has not been elucidated. Our results indicate that SV modulated the NK and adoptive T cell immune responses in antitumor efficacy. Furthermore, antitumor effects of SV were also mediated by innate myeloid cell function, which requires both TLR and β-glucan signaling in a MyD88/TRIF and Dectin-1-dependent manner, respectively. Additionally, SV treatment reduced granulocytic myeloid-derived suppressor cell (MDSC) infiltration into the tumor and limited monocytic MDSC toward the M2-like functional phenotype. Importantly, SV treatment enhanced antigen-specific immune responses by augmenting the activation of antigen-specific TH1/TH17 cells in secondary lymphoid organs and proliferative response, as well as by reducing the Treg population in the tumor microenvironment, which was driven by SV-primed activated M-MDSC. Our results support the idea that SV can subvert immune-tolerance state in the tumor microenvironment and inhibit tumor growth. The present study suggests that features, such as easy accessibility, favorable clinical efficacy, no detectable side effects and satisfactory safety make SV a feasible, appealing and convincing adjuvant therapy for the treatment of cancer patients and prevent tumor recurrence and/or metastases.

Indexed as

AnimalsCarcinoma, Non-Small-Cell LungDietary SupplementsDisease Models, AnimalImmune ToleranceImmunityLung NeoplasmsMiceMice, Inbred C57BLMice, Inbred NODMice, KnockoutMice, SCIDMice, TransgenicMonocytesMyeloid CellsMyeloid-Derived Suppressor CellsNutrientsPlant ExtractsCancer immunotherapyImmune modulating agentsMDSCNutrient supplementTH1

Identifiers

PMID33877384
PMCPMC10991198
OpenAlexW3156072713

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.